About DestiNA Genomics
DestiNA Genomics is a Healthcare company based in Edinburgh (United Kingdom) founded in 2010 by Hugh Ilyine and Juan Jose Diaz Mochon. Non-enzymatic nucleic acid detection technology is developed using DGL probes. DestiNA Genomics has raised $1.9 million across 11 funding rounds from investors including European Union. Its chief executive, as recorded, is Hugh Ilyine. DestiNA Genomics offers products and services including Assay Kits, LiverAce, ChemiRNA Tech, and Custom PNA synthesis. Its focus areas include Life Sciences, Life Sciences Platforms and Tools, Research Reagents and Kits and Probes and Dyes. Its legal entity is DESTINA GENOMICS LTD.
Company details
DestiNA Genomics was founded in 2010 in Edinburgh, United Kingdom, within the genomics sector. Non-enzymatic detection technology is created through dynamic chemistry, featuring DGL probes that integrate aldehyde-modified nucleobases with peptide nucleic acid. Binding to target sequences is facilitated, leaving blanks at deletion or mutation sites to minimize false positives over enzymatic methods. Applications cover insertions, deletions, mutations, and non-mutated nucleic acid sequences.
- Headquarters Edinburgh, United Kingdom
- Founders Hugh Ilyine, Juan Jose Diaz Mochon
- SectorsHealthcare
- Email••••••••
- Website destinagenomics.com
- Social LinkedIn X Facebook YouTube
- Legal Name Destina Genomics Ltd
- Date of Incorporation 28 Apr, 2010
- Jurisdiction EDINBURGH
- Total Equity Funding$1.9M (USD)
in 11 rounds
- Latest Funding Round$248.7K (USD), Grant
Nov 2022
- Investors
Products & Services of DestiNA Genomics
DestiNA Genomics offers a comprehensive portfolio of products and services, including Assay Kits, LiverAce, ChemiRNA Tech, and Custom PNA synthesis.
Kits for nucleic acid testing and RNA detection in research.
Kit for detecting liver injury through miRNA profiling.
Method for direct quantification of miRNAs from body fluids.
Custom design and supply of peptide nucleic acids for clients.
Apps and channels of DestiNA Genomics
its YouTube channel DESTINA Genomics Ltd. has 15 subscribers and 4 videos.
Videos from DestiNA Genomics
The most watched videos on DestiNA Genomics's YouTube channel, DESTINA Genomics Ltd. (15 subscribers). Click a video to play it here.
More on DESTINA Genomics Ltd..
Funding Insights of DestiNA Genomics
DestiNA Genomics has successfully raised a total of $1.9M across 11 strategic funding rounds. The most recent funding activity was a Grant round of $248.7 thousand completed in November 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $1.9M
- Total Rounds 11
- Last Round Grant — $248,701
- Investors Count 1
Latest 10 of 11 funding rounds of DestiNA Genomics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov 2022 | $248,701 | Grant | – | – | |
| Jan 2021 | $282,066 | Grant | – | – | |
| Jan 2019 | $478,959 | Grant | – | – | |
| May 2017 | $403,939 | Seed | – | – | – |
| Jan 2016 | $419,502 | Grant | – | – | |
| Dec 2015 | $133,880 | Grant | – | – | |
| Jul 2014 | $824,086 | Seed | – | – | – |
| Aug 2012 | $341,835 | Seed | – | – | – |
| Mar 2011 | $128,743 | Seed | – | – | – |
| Dec 2010 | $202,149 | Seed | – | – | – |
1 investors in total: 1 institutional.
Investors in DestiNA Genomics
DestiNA Genomics has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include European Union.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability | 1958 | europa.eu | Brussels, Belgium |
Investor details for DestiNA Genomics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of DestiNA Genomics
2 people are tracked at DestiNA Genomics (2 in leadership).
| Name | Role | Group |
|---|---|---|
Hugh Ilyine | Co-Founder & CEO | Leadership |
Juan Jose Diaz Mochon | Co-Founder | Leadership |
Complete people profiles for DestiNA Genomics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of DestiNA Genomics
3 dated milestones of DestiNA Genomics across 12 years, from founding to its latest funding, stage changes and deals.
- Founded DestiNA Genomics is founded.
- Funding First funding round.
- Funding Latest funding round, Grant, of $249K.
Web traffic of DestiNA Genomics
The website of DestiNA Genomics (destinagenomics.com) receives about 1.1K visits a month.
- Monthly visits1.1K
Top companies in Genomics & Gene Therapy Platforms
2 companies that operate in the same segment as DestiNA Genomics (Genomics & Gene Therapy Platforms) in United Kingdom, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.34 B | USD 301.49 M | 1,372 | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Destina Genomics
Complete news archive for DestiNA Genomics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about DestiNA Genomics
DestiNA Genomics was founded in 2010.
DestiNA Genomics is headquartered in Edinburgh, United Kingdom. It is registered at Edinburgh, Scotland, United Kingdom.
Hugh Ilyine is the CEO of DestiNA Genomics, as recorded in our data. They have also founded this company.
DestiNA Genomics is a funded company, having raised a total of $1.9M across 11 funding rounds to date. The company's 1st funding round was a Seed of $202.15K, raised on Oct 2010.
DestiNA Genomics was founded in 2010 in Edinburgh, United Kingdom, within the genomics sector. Non-enzymatic detection technology is created through dynamic chemistry, featuring DGL probes that integrate aldehyde-modified nucleobases with peptide nucleic acid. Binding to target sequences is facilitated, leaving blanks at deletion or mutation sites to minimize false positives over enzymatic methods. Applications cover insertions, deletions, mutations, and non-mutated nucleic acid sequences.
DestiNA Genomics offers Assay Kits, LiverAce, ChemiRNA Tech, and Custom PNA synthesis.
DestiNA Genomics has 1 investor. Key investors include European Union.
DestiNA Genomics operates through Destina Genomics Ltd.